Apellis Pharmaceuticals, Inc.

The European Medicines Agency hit a 15-year high for positive drug recommendations in 2024, with 114 new medicines gaining a positive opinion for regulatory approval across the EU from its human medic

Outlook Therapeutics is remaining hopeful that the US Food and Drug Administration will approve ONS-5010 for wet age-related macular degeneration (AMD) despite the Phase III NORSE EIGHT study not meet

Outlook Therapeutics is remaining hopeful that the US Food and Drug Administration will approve its ONS-5010 bevacizumab candidate for wet age-related macular degeneration (AMD) despite the Phase III

Novartis AG is looking to add a third indication to the label of Fabhalta (iptacopan) on the back of Phase III data in C3 glomerulopathy (C3G), a disease that has no US Food and Drug Administration-ap